Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells.
D000813:Anilides / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D015153:Blotting, Western; D001854:Bone Marrow Cells / Q000187:drug effects / Q000502:physiology; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002839:Chromans / Q000494:pharmacology; D004268:DNA-Binding Proteins / Q000187:drug effects / Q000502:physiology*; D015536:Down-Regulation; D024202:Electrophoretic Mobility Shift Assay; D004797:Enzyme-Linked Immunosorbent Assay; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D015850:Interleukin-6 / Q000494:pharmacology / Q000502:physiology*; D009101:Multiple Myeloma / Q000378:metabolism*; D020025:Peroxisome Proliferators / Q000494:pharmacology; D011233:Precipitin Tests; D011743:Pyrimidines / Q000494:pharmacology; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D050796:STAT3 Transcription Factor; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D045162:Thiazolidinediones / Q000494:pharmacology; D015534:Trans-Activators / Q000187:drug effects / Q000502:physiology*; D014157:Transcription Factors / Q000819:agonists / Q000378:metabolism*; D014158:Transcription, Genetic / Q000502:physiology*; D015533:Transcriptional Activation / Q000187:drug effects; D014162:Transfection; D000077288:Troglitazone
C457499:2-chloro-5-nitrobenzanilide; D000813:Anilides; D000970:Antineoplastic Agents; D002839:Chromans; D004268:DNA-Binding Proteins; D015850:Interleukin-6; D020025:Peroxisome Proliferators; D011743:Pyrimidines; D018160:Receptors, Cytoplasmic and Nuclear; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D045162:Thiazolidinediones; D015534:Trans-Activators; D014157:Transcription Factors; C006253:pirinixic acid; D000077288:Troglitazone